NCT03643900View on ClinicalTrials.gov

The Efficacy of Pancreatic Duct Stenting With Rectal Indomethacin in Preventing Post-ERCP Pancreatitis

NACompletedINTERVENTIONAL
Enrollment

618

Participants

Timeline

Start Date

August 8, 2018

Primary Completion Date

August 18, 2021

Study Completion Date

August 18, 2021

Conditions
Post-ERCP PancreatitisPancreatitis, Acute Necrotizing
Interventions
DEVICE

pancreatic duct stenting

Place the pancreatic duct stent

DRUG

rectal indomethacin

rectal indomethacin 100mg at preoperative 30min

Trial Locations (1)

31006

Hangzhou First People's Hospital, Hangzhou

All Listed Sponsors
lead

First People's Hospital of Hangzhou

OTHER

NCT03643900 - The Efficacy of Pancreatic Duct Stenting With Rectal Indomethacin in Preventing Post-ERCP Pancreatitis | Biotech Hunter | Biotech Hunter